Pursuing advancement together

Join us at the International Neuromodulation Society (INS) 2022 World Congress

21 – 26 May 2022, Barcelona, Spain
Follow us on LinkedIn and use #INS2022 to join the conversation.


Upcoming events


Clinical and scientific presentations

Spinal Cord Stimulation


Capturing the Chronic Pain Patient Experience Using a Novel Digital Ecosystem 
Monday, 23 May from 17:30–17:40 in Room 114 
Presented by: Simon Thomson, MBBS, FRCA, FFPMRCA 

Comprehensive Digital Tools to Improve Access to Care and Treatment Efficiency for Spinal Cord Stimulation 
Monday, 23 May from 17:40–17:50 in Room 114   
Presented by: Henry Vucetic, MD

Artificial Intelligence-Driven Closed-Loop SCS:  Early Patient Feedback on Personalized Therapy Recommendations from a Digital Health Assistant 
Monday, 23 May from 17:50–18:00 in Room 114  
Presented by: Richard Rauck, MD 

Pain Relief Outcomes Using Peripheral Nerve Field Stimulation (PNFS) Combined with Spinal Cord Stimulation in Chronic Pain 
Monday, 23 May from 18:10–18:20 in Room 116–117  
Presented by: Paolo Maino, MD 

COMBO RCT: Two-Year Outcomes of an SCS System Capable of Simultaneous Delivery of Multiple Modalities 
Wednesday, 25 May from 16:30–16:40 in Room 115  
Presented by: Richard Rauck, MD 

Long-Term Chronic Pain-Relief Outcomes Using an SCS System Capable of Combination Therapy 
Wednesday, 25 May from 17:20–17:30 in Room 115  
Presented by: Henry Vucetic, MD

Patient States: Artificial Intelligence-Driven Metric Providing Comprehensive Yet Straightforward Understanding of Chronic Pain Patients 
Wednesday, 25 May from 17:50–18:00 in Room 115  
Presented by: Magdalena Anitescu, MD, PhD   

Improved Outcomes and Pain Relief Using Novel Fast-Acting Sub-Perception SCS 
Wednesday, 25 May from 18:00–18:10 in Room 115  
Presented by: Louis Raso, MD 

Outcomes of Previously-Implanted SCS Chronic Pain Patients Converted to New SCS System — European Experience 
Thursday, 26 May from 10:30–10:40 in Room 114  
Presented by: Philippe Rigoard, MD, PhD  

Treatment of Upper Limb and Neck Pain Using Patient-Specific SCS Programming and Neural Targeting Capabilities 
Thursday, 26 May from 11:00–11:10 in Room 116–117  
Presented by: Sylvie Raoul, MD, PhD  

The Vertiflex™ Procedure†


Real-World, Prospective, Multi-Center Study Outcomes Using an Interspinous Spacer for Lumbar Spinal Stenosis
Sayed et al.

Treating Symptomatic Adjacent Segment Disease after lumbar spinal fusion with interspinous spacers: a multicenter observational case series
Mehta et al.

Clinical outcomes in a highly comorbid population using interspinous spacers for the treatment of Lumbar Spinal Stenosis
Naidu et al.

Real World Evaluation of Patients Using an Interspinous Spacer for the Treatment of Lumbar Spinal Stenosis
Esposito et al.

Treating Multiple Levels of Lumbar Spinal Stenosis with a Minimally-Invasive Interspinous Spacer Implanted 
Esposito et al.

Claims-Based Analysis of the Care Pathway (Conservative and Surgical Treatments) of patients with Lumbar Spinal Stenosis in the US
Naidu et al.

Biomechanical Impact of Interspinous spacers on sagittal alignment in patients with Lumbar Spinal Stenosis
Antony et al.

Radiofrequency Ablation


RAPID: An International, Prospective, Multicenter Study of Radiofrequency Ablation Outcomes in Chronic Pain Patients
Atallah et al.

Treatment of Chronic Knee Pain Using Radiofrequency Ablation: Multicenter, Real-World Observational Study
Atallah et al.

Real-World Outcomes Using Pulsed or Thermal Radiofrequency Ablation for Treatment of Chronic Pain in Europe
Occhigrossi et al.

Deep Brain Stimulation


Long-Term Motor Function and Quality of Life Outcomes from a Prospective, International DBS Registry 
Tuesday, 24 May from 16:40–16:50 in Room 113  
Presented by: Jan Vesper, MD, PhD 

Real-World Deep Brain Stimulation Outcomes Using Directional DBS Systems* with Multiple Independent Current Control 
Tuesday, 24 May from 17:00–17:10 in Room 113 
Presented by: Jens Volkmann, MD, PhD    

Real-World Outcomes Using Novel Directional DBS Systems for Parkinson's Disease 
Tuesday, 24 May from 17:10–17:20 in Room 113  
Presented by: Jan Vesper, MD, PhD 

Visualization Tool for DBS Programming with a Multiple-Source, Constant Current System Reduces Initial Programming Time
Aldred et al.

Prospective, Multicenter, International Registry of Deep Brain Stimulation for Essential Tremor
Deuschl et al.

U.S. Federal Government Employees – U.S. Federal Government Employees may be required to obtain approval from their agency’s or institution’s ethics officer or ethics committee or from a supervisor to attend this program. For more details, please contact your ethics officer or supervisor.

Vermont-Licensed HCPs – Vermont law prohibits Boston Scientific from providing any food, meals or refreshments at no charge to health care professionals licensed by and regularly practicing in Vermont. Accordingly, health care professionals licensed by and regularly practicing in Vermont are requested not to partake in any of the food, meals or refreshments offered at this event.

All U.S. Physicians – The U.S. Physician Payment Sunshine Act requires all pharmaceutical, biologics and medical device companies to disclose annually to the U.S. government payments and transfers of value provided to U.S. physicians and teaching hospitals. This includes the value of meals and refreshments provided to U.S. physicians in connection with attending Boston Scientific educational programs.


†Superion™ Indirect Decompression System

*A System that includes the Vercise™ PC, Vercise Gevia™, or Vercise Genus™ IPG and Vercise Cartesia™ Directional Lead(s) forms the Vercise Directional System


The WaveWriter Alpha™ SCS System provides safe access to full-body MRI scans when used with specific components and the patient is exposed to the MRI environment under the defined conditions in the ImageReady™ MRI Full Body Guidelines for WaveWriter Alpha and WaveWriter Alpha Prime Spinal Cord Stimulator System.

Subperception stimulation has been demonstrated to be safe and effective in patients who have been treated successfully with conventional, paresthesia-inducing stimulation for at least six months. Full stimulation parameter ranges and options for both paresthesia-based and subperception therapy are available for clinician’s use throughout the patient’s experience and treatment with SCS.

FAST MOA computational modeling by Dr. Warren Grill’s lab at Duke University. Gilbert et al., Computational modeling predicts dorsal columns are involved in fast-acting sub-perception spinal cord stimulation (SCS). SFN 2021.

The mySCS™ SmartCare app is currently not available for use in the EU, UK, or EFTA. For further information, please contact your Boston Scientific representative or distributor.

US Indications for Use. The Boston Scientific Spinal Cord Stimulator Systems are indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs including unilateral or bilateral pain associated with the following: failed back surgery syndrome, Complex Regional Pain Syndrome (CRPS) Types I and II, intractable low back pain and leg pain. Associated conditions and etiologies may be: radicular pain syndrome, radiculopathies resulting in pain secondary to failed back syndrome or herniated disc, epidural fibrosis, degenerative disc disease (herniated disc pain refractory to conservative and surgical interventions), arachnoiditis, multiple back surgeries.

Contraindications, warnings, precautions, side effects. The SCS Systems are contraindicated for patients who: are unable to operate the SCS System, have failed trial stimulation by failing to receive effective pain relief, are poor surgical risks, or are pregnant. Refer to the Instructions for Use provided with the SCS System or Pain.com for potential adverse effects, warnings, and precautions prior to using this product.

Caution: U.S. Federal law restricts this device to sale by or on the order of a physician.

The Boston Scientific Radiofrequency Generators, associated Radiofrequency Lesion Probes and RF Cannula are indicated for use in procedures to create radiofrequency lesions for the treatment of pain or for lesioning only peripheral nerve tissue for functional neurosurgical procedures. The Boston Scientific RF Injection Electrodes are used for percutaneous nerve blocks with local anesthetic solution or for radiofrequency lesioning of peripheral nerve tissue only. The Boston Scientific LCED and Stereotactic TCD Electrodes are indicated for use in radiofrequency (RF) heat lesioning of nervous tissue including the Central Nervous System. Warnings: The Boston Scientific RF devices may cause interference with active devices such as neurostimulators, cardiac pacemakers, and defibrillators. Interference may affect the action of these active devices or may damage them. For appropriate guidance, consult the instructions for use for these active devices. Refer to the Instructions for Use provided with Boston Scientific generators, electrodes and cannulas for potential adverse effects, warnings and precautions prior to using these products. Caution: U.S. Federal law restricts this device to sale by or on the order of a physician.

OUS Indications for Use: CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at www.IFU-BSCI.com. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France.


Indications for Use: The Superion™ Indirect Decompression System (IDS) is indicated to treat skeletally mature patients suffering from pain, numbness, and/or cramping in the legs (neurogenic intermittent claudication) secondary to a diagnosis of moderate degenerative lumbar spinal stenosis, with or without Grade 1 spondylolisthesis, having radiographic evidence of thickened ligamentum flavum, narrowed lateral recess, and/or central canal or foraminal narrowing. The Superion™ Interspinous Spacer is indicated for those patients with impaired physical function who experience relief in flexion from symptoms of leg/buttock/groin pain, with or without back pain, who have undergone at least 6 months of non-operative treatment. The Superion Interspinous Spacer may be implanted at one or two adjacent lumbar levels in patients in whom treatment is indicated at no more than two levels, from L1 to L5. Contraindications, warnings, precautions, side effects. The Superion Indirect Decompression System (IDS) is contraindicated for patients who: have spinal anatomy that prevent implantation of the device or cause the device to be unstable in situ (i.e., degenerative spondylolisthesis greater than grade 1), Cauda equina syndrome, or prior decompression or fusion at the index level. Refer to the Instructions for Use provided on www.vertiflex.com for additional Indications for Use, contraindications information and potential adverse effects, warnings, and precautions prior to using this product. Caution: U.S. Federal law restricts this device to sale by or on the order of a physician.

The Superion Indirect Decompression System is CE marked, but not yet available for sale in the EU, UK, or EFTA. For more specifics and further information, please contact your Boston Scientific representative or distributor.


US Indications for Use: The Boston Scientific Vercise™ PC, Vercise Gevia™, Vercise Genus™ Deep Brain Stimulation Systems are indicated for use in:

  • Bilateral stimulation of the subthalamic nucleus (STN) as an adjunctive therapy in reducing some of the symptoms of moderate to advanced levodopa responsive Parkinson’s disease (PD) that are not adequately controlled with medication.

  • Bilateral stimulation of the internal globus pallidus (GPi) as an adjunctive therapy in reducing some of the symptoms of advanced levodopa responsive Parkinson’s disease (PD) that are not adequately controlled with medication.  

  • Unilateral thalamic stimulation of the ventral intermediate nucleus (VIM) is indicated for the suppression of tremor in the upper extremity. The system is intended for use in patients who are diagnosed with essential tremor or parkinsonian tremor not adequately controlled by medications and where the tremor constitutes a significant functional disability.                        

The Boston Scientific Vercise Deep Brain Stimulation System is indicated for use in:

  • Bilateral stimulation of the subthalamic nucleus (STN) as an adjunctive therapy in reducing some of the symptoms of moderate to advanced levodopa responsive Parkinson’s disease (PD) that are not adequately controlled with medication.

Contraindications, warnings, precautions, side effects: The Deep Brain Stimulation Systems or any of its components, is contraindicated for: Diathermy as either a treatment for a medical condition or as part of a surgical procedure, Electroconvulsive Therapy (ECT) and Transcranial Magnetic Stimulation (TMS) as the safety of these therapies in patients implanted with the Vercise™ DBS System has not been established, patients who are unable to operate the system, patients who are poor surgical candidates or who experience unsuccessful test stimulation. Patients implanted with Boston Scientific Deep Brain Stimulation Systems without ImageReady™ MRI Technology should not be exposed to Magnetic Resonance Imaging (MRI). Patients implanted with Vercise Gevia™ or Vercise Genus™ or Vercise DBS Lead-only system (before Stimulator is implanted) with ImageReady MRI Technology are Full Body MR Conditional only when exposed to the MRI environment under the specific conditions defined in ImageReady MRI Guidelines for Boston Scientific Deep Brain Stimulation Systems. Assess patients for the risks of depression and suicide. This assessment should consider both the risk of depression and suicide as well as the potential clinical benefits of DBS therapy. Monitor patients for new or worsening symptoms of depression, suicidal thoughts or behaviors, or changes in mood or impulse control and manage appropriately. Refer to the Instructions for Use provided with the Vercise DBS System or BostonScientific.com for potential adverse effects, warnings, and precautions prior to using this product.

Caution: U.S. Federal law restricts this device to sale by or on the order of a physician.

OUS Indications for Use: CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at www.IFU-BSCI.com. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France.